India's Alembic Pharmaceuticals up on US drug regulator approval for leukemia tablets

Alembic Pharmaceuticals

01/07/2024 07:08

** Shares of Alembic Pharmaceuticals  ALEM.NS  rise 4.4% to
913.5 rupees
    ** Co receives U.S. FDA tentative approval for Bosutinib
tablets, used to treat a type of leukemia called Philadelphia
chromosome-positive chronic myelogenous leukemia
    ** Stock on track to reverse a 3-day streak of losses, if
gains hold
    ** Average rating of 11 analysts covering the stock
equivalent of "hold," median PT at 922.50 rupees
    ** Including session's gains, stock has risen ~20.1% YTD
    

 (Reporting by Yagnoseni Das in Bengaluru)
 ((Yagnoseni.das@thomsonreuters.com))